Inspire Medical Systems (NYSE:INSP) Price Target Raised to $77.00

Inspire Medical Systems (NYSE:INSP) had its price objective upped by Robert W. Baird from $73.00 to $77.00 in a research report sent to investors on Tuesday morning,Benzinga reports. The firm currently has a neutral rating on the stock.

A number of other research firms also recently commented on INSP. Evercore set a $54.00 target price on shares of Inspire Medical Systems in a research report on Tuesday, August 4th. Zacks Research lowered shares of Inspire Medical Systems from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 22nd. KeyCorp reissued a “sector weight” rating on shares of Inspire Medical Systems in a report on Tuesday, August 4th. Mizuho set a $75.00 price target on Inspire Medical Systems in a research note on Tuesday, October 13th. Finally, Truist Financial raised their price target on Inspire Medical Systems from $62.00 to $78.00 and gave the stock a “hold” rating in a research note on Wednesday, October 14th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $71.24.

Inspire Medical Systems Stock Down 0.2%

Shares of INSP stock opened at $66.45 on Tuesday. The company has a 50 day moving average price of $68.89 and a 200-day moving average price of $58.38. Inspire Medical Systems has a 52 week low of $38.91 and a 52 week high of $147.03. The firm has a market capitalization of $1.93 billion, a PE ratio of 32.81, a P/E/G ratio of 4.87 and a beta of 0.67.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings data on Monday, November 2nd. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.05. The firm had revenue of $206.69 million during the quarter, compared to analysts’ expectations of $204.31 million. Inspire Medical Systems had a net margin of 11.43% and a return on equity of 7.32%. The firm’s quarterly revenue was down 7.9% on a year-over-year basis. During the same period in the previous year, the company earned $0.38 earnings per share. Analysts anticipate that Inspire Medical Systems will post 1.29 earnings per share for the current year.

Hedge Funds Weigh In On Inspire Medical Systems

Several institutional investors have recently made changes to their positions in the business. EverSource Wealth Advisors LLC grew its position in shares of Inspire Medical Systems by 1,115.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 632 shares of the company’s stock valued at $33,000 after acquiring an additional 580 shares during the period. Versant Capital Management Inc raised its holdings in Inspire Medical Systems by 379.0% in the 2nd quarter. Versant Capital Management Inc now owns 958 shares of the company’s stock worth $43,000 after purchasing an additional 758 shares during the period. GAMMA Investing LLC raised its holdings in Inspire Medical Systems by 85.0% in the 2nd quarter. GAMMA Investing LLC now owns 1,221 shares of the company’s stock worth $54,000 after purchasing an additional 561 shares during the period. Sterling Capital Management LLC raised its holdings in Inspire Medical Systems by 450.6% in the 3rd quarter. Sterling Capital Management LLC now owns 914 shares of the company’s stock worth $63,000 after purchasing an additional 748 shares during the period. Finally, State of Wyoming lifted its position in Inspire Medical Systems by 83.7% during the first quarter. State of Wyoming now owns 1,343 shares of the company’s stock valued at $69,000 after purchasing an additional 612 shares in the last quarter. Institutional investors own 94.91% of the company’s stock.

Trending Headlines about Inspire Medical Systems

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Piper Sandler and Robert W. Baird were reported as expecting the stock to appreciate, offering some support amid weaker sentiment. Piper Sandler forecast Baird forecast
• Positive Sentiment: A bullish analysis argued Inspire’s competitive advantage held up under a severe stress test, suggesting the company may retain durable long-term strengths. Bullish competitive-position analysis
• Neutral Sentiment: Q3 results were mixed: revenue of $206.7 million modestly exceeded estimates, while falling 7.9% year over year; reported EPS of $0.14 beat the $0.09 consensus but was below $0.38 a year earlier. This points to continued growth and profitability concerns despite the estimate beats. Q3 earnings call summary
• Negative Sentiment: Inspire narrowed its full-year 2026 earnings guidance, a signal investors may interpret as reduced visibility or a weaker outlook. 2026 guidance update
• Negative Sentiment: Barclays maintained its Sell rating, and coverage linked an analyst downgrade to a sharp decline in the shares. This adds pressure alongside questions about cash flow and whether the stock has fallen enough. Barclays rating Cash-flow valuation discussion

About Inspire Medical Systems

Inspire Medical Systems, Inc develops and commercializes medical devices for the treatment of obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly narrows or becomes blocked during sleep. The company’s primary product is Inspire therapy, an implantable system designed to help keep the airway open by stimulating the hypoglossal nerve, which controls muscles involved in maintaining airway patency.

Inspire therapy is intended for certain adults with moderate to severe OSA who are unable to use or obtain consistent benefit from continuous positive airway pressure (CPAP) therapy.